Bradley S Hanberry1, Ryan Berger, Jason A Zastre. 1. Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, University of Georgia, R.C. Wilson Pharmacy Building, Athens, GA, 30602, USA.
Abstract
PURPOSE: The dichotomous effect of thiamine supplementation on cancer cell growth is characterized by growth stimulation at low doses and growth suppression at high doses. Unfortunately, how thiamine reduces cancer cell proliferation is currently unknown. Recent focuses on metabolic targets for cancer therapy have exploited the altered regulation of the thiamine-dependent enzyme pyruvate dehydrogenase (PDH). Cancer cells inactivate PDH through phosphorylation by overexpression of pyruvate dehydrogenase kinases (PDKs). Inhibition of PDKs by dichloracetate (DCA) exhibits a growth suppressive effect in many cancers. Recently, it has been shown that the thiamine coenzyme, thiamine pyrophosphate reduces PDK-mediated phosphorylation of PDH. Therefore, the objective of this study was to determine whether high-dose thiamine supplementation reduces cell proliferation through a DCA-like mechanism. METHODS: Cytotoxicity of thiamine and DCA was assessed in SK-N-BE and Panc-1 cancer cell lines. Comparative effects of high-dose thiamine and DCA on PDH phosphorylation were measured by Western blot. The metabolic impact of PDH reactivation was determined by glucose and lactate assays. Changes in the mitochondrial membrane potential, reactive oxygen species (ROS) production, and caspase-3 activation were assessed to characterize the mechanism of action. RESULTS: Thiamine exhibited a lower IC50 value in both cell lines compared with DCA. Both thiamine and DCA reduced the extent of PDH phosphorylation, reduced glucose consumption, lactate production, and mitochondrial membrane potential. High-dose thiamine and DCA did not increase ROS, but increased caspase-3 activity. CONCLUSION: Our findings suggest that high-dose thiamine reduces cancer cell proliferation by a mechanism similar to that described for dichloroacetate.
PURPOSE: The dichotomous effect of thiamine supplementation on cancer cell growth is characterized by growth stimulation at low doses and growth suppression at high doses. Unfortunately, how thiamine reduces cancer cell proliferation is currently unknown. Recent focuses on metabolic targets for cancer therapy have exploited the altered regulation of the thiamine-dependent enzyme pyruvate dehydrogenase (PDH). Cancer cells inactivate PDH through phosphorylation by overexpression of pyruvate dehydrogenase kinases (PDKs). Inhibition of PDKs by dichloracetate (DCA) exhibits a growth suppressive effect in many cancers. Recently, it has been shown that the thiamine coenzyme, thiamine pyrophosphate reduces PDK-mediated phosphorylation of PDH. Therefore, the objective of this study was to determine whether high-dose thiamine supplementation reduces cell proliferation through a DCA-like mechanism. METHODS:Cytotoxicity of thiamine and DCA was assessed in SK-N-BE and Panc-1cancer cell lines. Comparative effects of high-dose thiamine and DCA on PDH phosphorylation were measured by Western blot. The metabolic impact of PDH reactivation was determined by glucose and lactate assays. Changes in the mitochondrial membrane potential, reactive oxygen species (ROS) production, and caspase-3 activation were assessed to characterize the mechanism of action. RESULTS:Thiamine exhibited a lower IC50 value in both cell lines compared with DCA. Both thiamine and DCA reduced the extent of PDH phosphorylation, reduced glucose consumption, lactate production, and mitochondrial membrane potential. High-dose thiamine and DCA did not increase ROS, but increased caspase-3 activity. CONCLUSION: Our findings suggest that high-dose thiamine reduces cancer cell proliferation by a mechanism similar to that described for dichloroacetate.
Authors: K Meador; D Loring; M Nichols; E Zamrini; M Rivner; H Posas; E Thompson; E Moore Journal: J Geriatr Psychiatry Neurol Date: 1993 Oct-Dec Impact factor: 2.680
Authors: B Comín-Anduix; J Boren; S Martinez; C Moro; J J Centelles; R Trebukhina; N Petushok; W N Lee; L G Boros; M Cascante Journal: Eur J Biochem Date: 2001-08
Authors: S J Yeaman; E T Hutcheson; T E Roche; F H Pettit; J R Brown; L J Reed; D C Watson; G H Dixon Journal: Biochemistry Date: 1978-06-13 Impact factor: 3.162
Authors: Victoria I Bunik; Artem Artiukhov; Alexey Kazantsev; Renata Goncalves; Danilo Daloso; Henry Oppermann; Elena Kulakovskaya; Nikolay Lukashev; Alisdair Fernie; Martin Brand; Frank Gaunitz Journal: Oncotarget Date: 2015-11-24
Authors: Xiaowen Liu; Sophia Montissol; Amy Uber; Sarah Ganley; Anne V Grossestreuer; Katherine Berg; Stanley Heydrick; Michael W Donnino Journal: Molecules Date: 2018-06-16 Impact factor: 4.411
Authors: Mohammad Hossein Norouzi-Beirami; Sayed-Amir Marashi; Ali Mohammad Banaei-Moghaddam; Kaveh Kavousi Journal: Front Microbiol Date: 2020-01-23 Impact factor: 5.640
Authors: Victoria I Bunik; Garik Mkrtchyan; Aneta Grabarska; Henry Oppermann; Danilo Daloso; Wagner L Araujo; Malgorzata Juszczak; Wojciech Rzeski; Lucien Bettendorff; Alisdair R Fernie; Jürgen Meixensberger; Andrzej Stepulak; Frank Gaunitz Journal: Oncotarget Date: 2016-05-03
Authors: Victoria I Bunik; Vasily A Aleshin; Xiaoshan Zhou; Vyacheslav Yu Tabakov; Anna Karlsson Journal: Int J Mol Sci Date: 2020-05-26 Impact factor: 5.923